Amyris, Inc. (AMRS)
$0.05
Rating:
Recommendation:
Buy
| Symbol | AMRS |
|---|---|
| Price | $0.05 |
| Beta | 1.189 |
| Volume Avg. | 23.76M |
| Market Cap | 18.469M |
| Shares () | - |
| 52 Week Range | 0.05-4.86 |
| 1y Target Est | - |
| DCF Unlevered | AMRS DCF -> | |
|---|---|---|
| DCF Levered | AMRS LDCF -> | |
| ROE | 136.68% | Strong Buy |
| ROA | -92.43% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -155.71% | Sell |
| P/E | -0.04 | Neutral |
| P/B | -0.03 | Neutral |
Latest AMRS news
About
Download (Excel)Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.